VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BNGO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BNGOBionano Genomics, Inc.
$1.17$4M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBNGOCash Flow

Bionano Genomics, Inc. (BNGO) Cash Flow Statement

10Y historyFree accessUpdated daily

Free cash flow remains deeply negative, with a 2026Q1 margin of -85.5%, highlighting a structural inability to fund operations through internal cash generation.

BNGO Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Cash from Operations-19.3M-16.34M-68.92M-125.18M-124.82M-71.93M-38.31M-29.53M-19.94M-20.82M-23.5M
Operating CF Margin %--57.33%-223.95%-346.61%-448.95%-400.02%-450.59%-291.52%-166.19%-219.02%-345.9%
Operating CF Growth %68.98%76.28%44.94%-0.29%-73.53%-87.73%-29.75%-48.06%4.2%11.4%-
Net Income-31.6M-26.39M-112.02M-232.49M-132.6M-72.44M-41.11M-29.82M-18.5M-23.37M-18.85M
Depreciation & Amortization9.61M9.73M14.23M13.91M9.84M3.37M1.48M1.13M1.32M1.5M1.12M
Stock-Based Compensation2.01M4.53M9.74M15.18M22.42M9.72M1.55M1.35M1.31M382.83K130.64K
Deferred Taxes00001.76M-5.78M01.9M-2.46M479.01K-3.01M
Other Non-Cash Items2.82M-4.73M14.73M92.99M1.7M848K3.2M883.27K750.47K96.58K73.9K
Working Capital Changes-2.14M514K4.4M-14.77M-27.94M-7.65M-3.44M-4.97M-2.37M85.1K-2.96M
Change in Receivables-779K-448K4.14M-2.3M-2.25M-493K2.09M-2.37M-900.12K-1.77M-856.1K
Change in Inventory3.7M4.92M-587K-4.15M-23.68M-15.93M-4.2M-3.64M-418.98K-336.05K-726.14K
Change in Payables-1.5M-1.37M-3.42M-2M1.95M6.78M-1.81M1.36M-954.38K1.54M-608.65K
Cash from Investing6.78M-12.75M73.84M24.16M82.77M-278.06M-2.45M-61.06K-331.72K-1.02M-1.35M
Capital Expenditures00-103K-1.69M-3.2M-1.46M0-61.06K-331.72K-1.02M-1.35M
CapEx % of Revenue0%-0.33%4.68%11.51%8.12%-0.6%2.76%10.71%19.87%
Acquisitions00096K-31.34M-49.09M-2.45M0000
Investments-----------
Other Investing0000618K-607K00000
Cash from Financing13.8M24.04M-13.69M113.81M23.01M336.11M61.9M30.38M35.78M17.61M25.43M
Debt Issued (Net)-3.45M-4.95M-48.06M70.95M-36K-15.01M-4.72M9.82M16.38M01.89M
Equity Issued (Net)17.36M28.98M44.43M57.7M23.13M342.71M39.93M19.56M19.39M17.59M23.54M
Dividends Paid00000000000
Share Repurchases00000000000
Other Financing-104K0-10.06M-14.84M-85K8.4M26.69M1M3.5K14.29K1.96K
Net Change in Cash10.07M-5.06M-8.78M12.86M-19.08M-13.88M21.14M788.64K15.5M-4.23M584.85K
Free Cash Flow-19.3M-16.34M-69.03M-126.87M-128.12M-73.39M-38.31M-29.59M-20.28M-21.84M-24.85M
FCF Margin %-67.15%-57.33%-224.28%-351.29%-460.82%-408.14%-450.59%-292.12%-168.95%-229.73%-365.77%
FCF Growth %57.19%76.32%45.59%0.97%-74.58%-91.54%-29.48%-45.94%7.14%12.12%-
FCF per Share-3.54-3.00-36.28-218.54-260.58-155.97-216.19-69728.55-101117.44--
FCF Conversion (FCF/Net Income)0.61x0.62x0.62x0.54x0.94x0.99x0.93x0.99x1.08x0.89x1.25x
Interest Paid442K010.65M1.65M298K1.91M1.25M0000
Taxes Paid00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Acute liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Disconnect Between Earnings Reality

According to the provided financial data, the company consistently reports negative net income that significantly exceeds operating cash outflows, with OCF/NI ratios fluctuating between 0.30 and 1.38, suggesting that non-cash charges and working capital volatility are masking the true extent of the underlying cash burn.

The wide variance in the OCF/NI ratio indicates that accounting accruals and non-cash expenses, such as depreciation and stock-based compensation, are heavily influencing the reported cash flow figures. Investors should monitor this divergence, as it suggests that the company's operating cash flow is not yet a reliable proxy for its core business performance.

Negative Free Cash Flow Trajectory

As reported in recent quarterly filings, the company's free cash flow remains deeply negative, with margins reaching as low as -85.5% in 2026Q1, highlighting a structural inability to generate self-sustaining cash flow despite ongoing efforts to scale the Saphyr platform and expand the installed base.

The persistent negative FCF trajectory suggests that the company is currently in a capital-intensive phase where cash outflows are required to fund both operations and market penetration. This trend warrants further investigation into whether the current business model can achieve positive cash flow before the existing liquidity is exhausted.

Volatile Working Capital Management Trends

Based on the quarterly cash flow statements, working capital changes have been highly erratic, swinging from a $5.3M source of cash in 2024Q1 to a $6.2M use of cash in 2023Q4, which indicates significant instability in inventory management and accounts receivable collection cycles.

This volatility in working capital suggests that the company may be struggling to align its inventory procurement with actual customer demand, leading to inefficient cash usage. Such fluctuations often indicate operational friction that can exacerbate liquidity pressures during periods of slowing revenue growth.

Hidden Cash Flow Obfuscation Factors

Analysis of the cash flow statements reveals that stock-based compensation and depreciation charges are significant non-cash adjustments, with SBC reaching $3.4M in 2023Q4, which effectively obscures the true economic cost of operations and the dilution impact on existing shareholders over the observed period.

By relying on these non-cash adjustments to bridge the gap between net income and operating cash flow, the company may be presenting a more favorable liquidity picture than the underlying cash burn suggests. Analysts should be cautious of these adjustments, as they do not represent actual cash generation and may mask the true cost of talent retention and asset maintenance.

BNGO — Frequently Asked Questions

Quick answers to the most common questions about buying BNGO stock.

How much cash does Bionano Genomics, Inc. (BNGO) generate from operations?

Bionano Genomics, Inc. (BNGO) generated $-16.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Bionano Genomics, Inc.'s free cash flow?

Bionano Genomics, Inc. (BNGO) reported negative free cash flow of $16.3M in 2025, indicating capital requirements exceeded cash from operations.

What is Bionano Genomics, Inc.'s capital expenditure (CapEx)?

Bionano Genomics, Inc. (BNGO) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.